UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 319

Sortiert nach

Temporal trends, clinical patterns and outcomes of NAFLD‐related HCC in patients undergoing liver resection over a 20‐year period

Alimentary Pharmacology & Therapeutics (Suppl), 2017-11, Vol.46 (9), p.856-863

2017

Link zum Volltext

Verfügbarkeit prüfen

Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease

Alimentary pharmacology & therapeutics, 2014-11, Vol.40 (10), p.1209-1222

2014

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology

Atherosclerosis, 2014-01, Vol.232 (1), p.99-109

2014

Link zum Volltext

Verfügbarkeit prüfen

Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial

Nature Medicine, 2021-10, Vol.27 (10), p.1825-1835

2021

Link zum Volltext

Verfügbarkeit prüfen

Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages

Clinical chemistry (Baltimore, Md.), 2007-09, Vol.53 (9), p.1615-1622

2007

Link zum Volltext

Verfügbarkeit prüfen

Relationship between fatty liver, coronary calcium score, multiple-sites atherosclerosis and 10-years Framingham Score

Journal of hepatology, 2017, Vol.66 (1), p.S588-S589

2017

Link zum Volltext

Verfügbarkeit prüfen

P327 PROFILING NEW BIOMARKERS FOR THE DIAGNOSIS OF DRUG INDUCED LIVER NECROSIS. A PILOT STUDY ASSESSING PERFORMANCE OF CLEAVED OR FULL-LENGTH CYTOKERATIN 18, AND MICRO-RNA-122

Journal of hepatology, 2014-04, Vol.60 (1), p.S175-S175

2014

Link zum Volltext

Verfügbarkeit prüfen

Pharmacological agents for NASH

Nature reviews. Gastroenterology & hepatology, 2013-11, Vol.10 (11), p.676

Ratziu, Vlad

2013

Link zum Volltext

Verfügbarkeit prüfen

Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease

Clinics and research in hepatology and gastroenterology, 2011-01, Vol.35 (1), p.23-28

2011

Link zum Volltext

Verfügbarkeit prüfen

Impact of NASH, gender, fasting glucose and body mass index on the liver fibrosis transition rate (FTR) in metabolic liver disease (MLD)

Journal of hepatology, 2017, Vol.66 (1), p.S111-S111

2017

Link zum Volltext

Verfügbarkeit prüfen

Serum Bile Acid Profiles are Associated with Histological Severity in Patients with Non-Alcoholic Fatty Liver Disease

Journal of hepatology, 2016, Vol.64 (2), p.S495-S495

2016

Link zum Volltext

Verfügbarkeit prüfen

Regenerate: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Multicenter Study of Obeticholic Acid Therapy for Nonalcoholic Steatohepatitis

Journal of hepatology, 2016, Vol.64 (2), p.S294-S295

2016

Link zum Volltext

Verfügbarkeit prüfen

Histological progression of non‐alcoholic fatty liver disease: a critical reassessment based on liver sampling variability

Alimentary pharmacology & therapeutics, 2007-09, Vol.26 (6), p.821-830

2007

Link zum Volltext

Verfügbarkeit prüfen

Prediction of fibrosis improvement in patients with advanced fibrosis due to NASH using a machine learning approach: Unravelling the placebo response

Journal of hepatology, 2018, Vol.68, p.S97

2018

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of liver fibrosis and steatosis biomarkers in type‐2 diabetes and dyslipidaemia

Alimentary pharmacology & therapeutics, 2014-11, Vol.40 (9), p.1081-1093

2014

Link zum Volltext

Verfügbarkeit prüfen

345 A NEW METHODOLOGY FOR ASSESSING PROGRESSION OF LIVER FIBROSIS IN LARGE POPULATIONS USING VALIDATED BIOMARKER FIBROTEST® INSTEAD OF BIOPSY

Journal of hepatology, 2011-03, Vol.54, p.S138-S138

2011

Link zum Volltext

Verfügbarkeit prüfen

Letter: FibroTest for staging fibrosis in non‐alcoholic fatty liver disease

Alimentary pharmacology & therapeutics, 2013-03, Vol.37 (6), p.655-656

2013

Link zum Volltext

Verfügbarkeit prüfen

Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial

Journal of viral hepatitis, 2002-03, Vol.9 (2), p.128-133

2002

Link zum Volltext

Verfügbarkeit prüfen

Combination drug therapy allows synergistic therapeutic dose reduction in NASH: a case study of elafibranor (GFT505) and an FXR agonist combination in a model of severe NASH

Journal of hepatology, 2017, Vol.66 (1), p.S113-S113

2017

Link zum Volltext

Verfügbarkeit prüfen

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view

Gastroenterology (New York, N.Y. 1943), 1999-02, Vol.116 (2), p.378-386

1999

Link zum Volltext

Verfügbarkeit prüfen

Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis

Journal of hepatology, 2017, Vol.66 (1), p.S110-S111

2017

Link zum Volltext

Verfügbarkeit prüfen

Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies

Journal of hepatology, 2017, Vol.66 (1), p.S593-S593

2017

Link zum Volltext

Verfügbarkeit prüfen

Simple non-invasive fibrosis scores identify patients with non-alcoholic fatty liver disease who progress to advanced fibrosis/cirrhosis:evidence from a large cohort of patients with sequential liver biopsies

Journal of hepatology, 2017, Vol.66 (1), p.S68-S69

2017

Link zum Volltext

Verfügbarkeit prüfen

A new non-invasive diagnostic score to monitor change in disease activity and predict fibrosis evolution in patients with NASH

Journal of hepatology, 2017, Vol.66 (1), p.S110-S110

2017

Link zum Volltext

Verfügbarkeit prüfen

Advancing the global public health agenda for NAFLD: a consensus statement

Nature reviews. Gastroenterology & hepatology, 2022-01, Vol.19 (1), p.60-78

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 319

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(290)
Mit Volltextzugriff
(305)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Temporal trends, clinical patterns and outcomes of NAFLD‐related HCC in patients undergoing liver resection over a 20‐year period

Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease

Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology

Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial

Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages

Relationship between fatty liver, coronary calcium score, multiple-sites atherosclerosis and 10-years Framingham Score

P327 PROFILING NEW BIOMARKERS FOR THE DIAGNOSIS OF DRUG INDUCED LIVER NECROSIS. A PILOT STUDY ASSESSING PERFORMANCE OF CLEAVED OR FULL-LENGTH CYTOKERATIN 18, AND MICRO-RNA-122

Pharmacological agents for NASH

Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease

Impact of NASH, gender, fasting glucose and body mass index on the liver fibrosis transition rate (FTR) in metabolic liver disease (MLD)

Serum Bile Acid Profiles are Associated with Histological Severity in Patients with Non-Alcoholic Fatty Liver Disease

Regenerate: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Multicenter Study of Obeticholic Acid Therapy for Nonalcoholic Steatohepatitis

Histological progression of non‐alcoholic fatty liver disease: a critical reassessment based on liver sampling variability

Prediction of fibrosis improvement in patients with advanced fibrosis due to NASH using a machine learning approach: Unravelling the placebo response

Prognostic value of liver fibrosis and steatosis biomarkers in type‐2 diabetes and dyslipidaemia

345 A NEW METHODOLOGY FOR ASSESSING PROGRESSION OF LIVER FIBROSIS IN LARGE POPULATIONS USING VALIDATED BIOMARKER FIBROTEST® INSTEAD OF BIOPSY

Letter: FibroTest for staging fibrosis in non‐alcoholic fatty liver disease

Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial

Combination drug therapy allows synergistic therapeutic dose reduction in NASH: a case study of elafibranor (GFT505) and an FXR agonist combination in a model of severe NASH

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view

Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis

Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies

Simple non-invasive fibrosis scores identify patients with non-alcoholic fatty liver disease who progress to advanced fibrosis/cirrhosis:evidence from a large cohort of patients with sequential liver biopsies

A new non-invasive diagnostic score to monitor change in disease activity and predict fibrosis evolution in patients with NASH

Advancing the global public health agenda for NAFLD: a consensus statement

Suchergebnisse filtern